// App-Quantinova.ai

2935 : Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Researchers

Presenter

  • Ryan C. Lynch

Principal Investigators

  • Shankara Paneesha

  • Abraham Avigdor

  • Matthew S McKinney

  • Bjrn E Wahlin

  • John S Hrom

  • David Belada

  • Miguel Canales

  • David Cunningham

  • Liliana Devizzi

  • Nicholas Morley

  • Fred Zheng

  • Douglas J DeMarini

  • Wei Jiang

  • Marek Trnen

Medical Centers

  • Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

  • Centre for Haematology and Stem Cell Transplantation, Heartlands Hospital, Birmingham, United Kingdom

  • Sackler Faculty Of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  • Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel

  • Duke Cancer Institute, Durham, NC

  • Karolinska Institute, Department of Medicine Solna and Karolinska University Hospital, Department of Emergency Medicine, Stockholm, Sweden

  • Forrest General Hospital and Hattiesburg Clinic, Hattiesburg, MS

  • Fourth Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

  • Hospital Universitario La Paz, Madrid, Spain

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

  • Incyte Corporation, Wilmington, DE

  • 1st Department of Medicine - Department of Haematology,Charles University General Hospital,Prague,Czech Republic

Locations

  • United States

  • United Kingdom

  • Israel

  • Sweden

  • Czech Republic

  • Spain

  • Italy

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03126019

Sponsors

  • N/A

Result

  • N/A